# Study Guide: 2024 Management of Lower Extremity Peripheral Artery Disease This study guide provides a comprehensive overview of the "2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease." It is designed to synthesize key clinical concepts, diagnostic protocols, and risk factors to support deep understanding and practical application. --- ## Section 1: Key Concepts and Clinical Subsets Peripheral artery disease (PAD) is a cardiovascular condition affecting 10 to 12 million individuals in the United States. It is categorized into four distinct clinical subsets based on presentation and severity. ### Table 1: Clinical Subsets of PAD | Subset | Characterization and Symptoms | | :--- | :--- | | **Asymptomatic PAD** | Patients report no leg symptoms but may have functional impairment comparable to those with claudication. Often identified through objective testing. | | **Chronic Symptomatic PAD** | Includes typical claudication (fatigue, cramping, or pain induced by walking and relieved by rest within 10 minutes) and other non-joint-related exertional leg symptoms. | | **Chronic Limb-Threatening Ischemia (CLTI)** | A severe condition characterized by chronic (>2 weeks) ischemic rest pain, nonhealing wounds, ulcers, or gangrene. High risk for amputation and mortality. | | **Acute Limb Ischemia (ALI)** | A sudden decrease in limb perfusion (≤2 weeks) threatening viability. Symptoms include the "6 Ps": pain, pallor, pulselessness, poikilothermia, paresthesias, and paralysis. | ### Core Diagnostic Values * **Abnormal ABI:** ≤0.90 * **Borderline ABI:** 0.91–0.99 * **Normal ABI:** 1.00–1.40 * **Noncompressible ABI:** >1.40 * **Abnormal Toe-Brachial Index (TBI):** ≤0.70 --- ## Section 2: Risk Amplifiers and Health Disparities While PAD is primarily an atherosclerotic disease, several factors amplify the risk of Major Adverse Cardiovascular Events (MACE) and Major Adverse Limb Events (MALE). ### PAD-Related Risk Amplifiers * **Diabetes:** Increases risk of CLTI and is associated with a 5.48-fold increase in amputation risk. * **Chronic Kidney Disease (CKD):** Up to 25% of CKD patients have PAD; dialysis-dependent patients face the highest risk. * **Smoking:** 80%–90% of patients revascularized for severe symptoms are current smokers. * **Polyvascular Disease:** Atherosclerosis in ≥2 arterial beds (coronary, peripheral, or cerebrovascular) compounds cardiovascular risk. * **Microvascular Disease:** Retinopathy or neuropathy increases the risk of PAD 14-fold. * **Depression:** Associated with higher mortality, longer hospital stays, and increased amputation rates. ### Health Disparities The guideline highlights significant inequities in PAD outcomes: * **Race and Ethnicity:** Black individuals have a 2- to 4-fold higher risk of amputation than White individuals. Hispanic and American Indian populations also face higher rates of limb loss and lower rates of revascularization. * **Social Determinants of Health:** Chronic stress, lower health literacy, inadequate insurance, and limited access to quality food and exercise contribute to poorer outcomes. * **Sex:** Women often present 10 to 20 years later than men, frequently with more advanced disease and atypical symptoms. --- ## Section 3: Short-Answer Practice Questions **1. What is the specific timing threshold used to differentiate between Acute Limb Ischemia (ALI) and Chronic Limb-Threatening Ischemia (CLTI)?** *Answer:* ALI is defined by symptoms lasting ≤2 weeks, while CLTI is defined by symptoms lasting >2 weeks. **2. Which antithrombotic drug combination is specifically recommended to prevent MACE and MALE in patients with PAD who are not at increased risk of bleeding?** *Answer:* Rivaroxaban (2.5 mg twice daily) combined with low-dose aspirin (81 mg daily). **3. When should a Toe-Brachial Index (TBI) be performed instead of a resting Ankle-Brachial Index (ABI)?** *Answer:* TBI should be performed when the resting ABI is >1.40 (noncompressible), which often occurs in patients with diabetes or CKD. **4. What are the three components of the WIfI clinical staging system for CLTI?** *Answer:* Wound (extent), Ischemia (severity), and foot Infection. **5. Under what circumstances is anatomic imaging (CTA, MRA, or catheter angiography) contraindicated for patients with PAD?** *Answer:* These should not be performed solely for anatomic assessment in patients with a confirmed diagnosis if revascularization is not being considered (Class 3: Harm). **6. What are the "6 Ps" used to characterize the clinical presentation of Acute Limb Ischemia?** *Answer:* Pain, pallor, pulselessness, poikilothermia (coolness), paresthesias, and paralysis. --- ## Section 4: Essay Prompts for Deeper Exploration 1. **The Role of Structured Exercise in PAD Management:** Discuss why structured exercise is considered a "core component" of care for PAD. Compare supervised exercise therapy (SET) with community-based programs, and explain how exercise testing is used to assess functional status and response to therapy. 2. **Evaluating Clinical Decision-Making for Revascularization:** Analyze the criteria for recommending revascularization in patients with claudication versus those with CLTI. In your response, address the roles of Guideline-Directed Management and Therapy (GDMT), quality of life (QOL), and the prevention of limb loss. 3. **Systemic Bias and Limb Salvage:** Examine the evidence provided regarding racial and ethnic disparities in PAD treatment. How do structural racism and fragmented access to care impact the likelihood of a patient receiving a primary amputation versus a revascularization attempt? 4. **Managing the Multimorbid PAD Patient:** Discuss the intersection of PAD with risk amplifiers such as CKD, diabetes, and polyvascular disease. How do these comorbidities complicate diagnostic testing (e.g., ABI limitations) and influence the urgency of multispecialty care? --- ## Section 5: Glossary of Important Terms | Term | Definition | | :--- | :--- | | **ABI (Ankle-Brachial Index)** | Ratio of the higher systolic pressure in the pedal arteries to the higher of the two brachial artery systolic pressures. | | **Angiosome** | A skin region and underlying tissue supplied by a specific source artery. | | **Claudication** | Fatigue or pain in lower extremity muscles induced by walking and relieved by rest. | | **GDMT** | Guideline-Directed Management and Therapy; encompasses evaluation, testing, and both pharmacological and procedural treatments. | | **MACE** | Major Adverse Cardiovascular Events (e.g., death, MI, stroke). | | **MALE** | Major Adverse Limb Events (e.g., major amputation, revascularization, ALI). | | **PVR (Pulse Volume Recording)** | Plethysmographic tracings used to assess blood flow and localize arterial disease. | | **SET (Supervised Exercise Therapy)** | A structured exercise program in a hospital or outpatient facility supervised by qualified healthcare providers. | | **SPP (Skin Perfusion Pressure)** | A measure of local perfusion used to predict wound-healing potential. | | **TcPO2** | Transcutaneous oxygen pressure; used to assess arterial perfusion in suspected CLTI. | | **Weathering** | The impact of chronic stress from structural racism and health disparities on long-term physiological health. |